PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Gabapentin - Pain (Neuropathic)
PAD Profile : Gabapentin - Pain (Neuropathic) Important
Keywords :
diabetic neuropathy, postherpetic neuralgia, PHN, neuropathic pain
Brand Names Include :
Neurontin
Important Information :
First line gabapentinoid.
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Duloxetine hydrochloride
- Amitriptyline hydrochloride
- Pregabalin
- Nortriptyline
- Imipramine hydrochloride
- Dosulepin hydrochloride
- Tramadol hydrochloride
- Capsaicin
Other Indications
Additional Documents
Type
Document
Review Date
Guidelines (National)
Committee Recommendations
Date
Committee Name
Narrative
07 October 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Gabapentinoids are recommended as a teatment option at step 2 of the local neuropathic pain guidelines.
Gabapentin is preferential to pregabalin due to its lower potential for misuse.
Pregabalin may be used if gabapentin is effective but not well tolerated OR if gabapentin is ineffective.
Gabapentinoids are Controlled Drugs and a maximum supply of 30 days should be prescribed at any time.
See guidelines and other resources relating to the use of gabapentinoids below
03 February 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Prescribers are reminded to undertake a proportionate risk benefit assessment prior to prescribing Pregabalin or Gabapentin for patients with a known or suspected propensity to misuse.
See Advice to Prescribers document below
Associated BNF Codes
04. Central Nervous System
04.07.03. Neuropathic pain